摘要
目的分析埃克替尼靶向治疗对非小细胞肺癌(NSCLC)患者免疫功能及血清糖类抗原125(CA125)、胃泌素释放肽前体(pro-GRP)水平的影响。方法随机选取河南理工大学第一附属医院肿瘤科2017年1月至2018年12月收治的NSCLC患者100例作为研究对象,双盲法将其分成常规组(基础化疗方案GP)与治疗组(埃克替尼),每组50例。比较两组患者免疫功能、凝血功能、血清肿瘤标志物水平及不良反应。结果治疗组患者CD4^+(44.27±2.05)、CD4^+/CD8^+(1.47±0.28)、自然杀伤细胞(NK)(22.85±2.51)水平高于常规组(P<0.05),CD8+低于常规组(P<0.05)。治疗前两组患者癌胚抗原(CEA)、Cyfra21-1水平比较差异未见统计学意义(P>0.05),治疗后降低,其中治疗组患者CEA水平[(4.26±2.68)ng/ml]、Cyfra21-1水平[(12.57±3.54)ng/ml]低于常规组(P<0.05)。治疗前常规组及治疗组患者CA125、pro-GRP水平比较差异未见统计学意义(P>0.05),治疗后降低;其中治疗组患者CA125[(32.51±1.56)U/ml]、pro-GRP[(106.53±20.53)pg/ml]水平低于常规组(P<0.05)。结论埃克替尼靶向治疗能明显抑制NSCLC肿瘤细胞增殖,改善机体免疫功能及凝血功能,建议使用。
Objective To analyze the effect of exetane targeted therapy on the autoimmunity and levels of serum CA125,pro GRP on non small cell lung cancer(NSCLC)patients.Methods One hundred NSCLC patients admitted to the oncology department of the First Affiliated Hospital of Henan University of Technology from January 2017 to December 2018 were randomly selected as the research objects,and they were divided into the conventional group(GP)and the treatment group(exetinib)by double-blind method,with 50 cases in each group.The immune level,coagulation function,serum tumor markers and adverse reactions were compared between the two groups.Results The levels of CD4^+(44.27±2.05),CD4^+/CD8^+(1.47±0.28),NK(22859±2.51)in the treatment group were higher than those in the control group(P<0.05),and the level of CD8^+was lower than that in the control group(P<0.05).There was no significant difference in CEA or CYFRA21-1 levels between the routine group and the treatment group before treatment(P>0.05).The CEA[(4.26±2.68)ng/ml]and CYFRA21-1[(12.57±3.54)ng/ml]levels in the treatment group were lower than those in the routine group(P<0.05).There was no significant difference in CA125 or pro GRP levels between the routine group and the treatment group before treatment(P>0.05),but decreased after treatment.The CA125[(32.51±1.56)U/ml]and pro GRP[(106.53±20.53)pg/ml]levels in the treatment group were lower than those in the routine group after treatment(P<0.05).Conclusions Exetane targeting therapy can significantly inhibit the proliferation of NSCLC tumor cells,improve the immune function and coagulation function of the body,it is recommended to use.
作者
吕晶晶
李庆云
陈瑞霞
张芳
Lyu Jingjing;Li Qingyun;Chen Ruixia;Zhang Fang(The First Department of Oncology,the First Affiliated Hospital of Henan University of Technology(Jiaozuo Second People's Hospital),Jiaozuo 454000,China)
出处
《临床医学》
CAS
2020年第6期80-82,共3页
Clinical Medicine
